These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 31625262)
1. Three-year clinical outcome in all-comers with "silent" diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes study. Ploumen EH; Buiten RA; Kok MM; Doggen CJM; van Houwelingen KG; Stoel MG; de Man FHAF; Hartmann M; Zocca P; Linssen GCM; Doelman C; Kant GD; von Birgelen C Catheter Cardiovasc Interv; 2020 Aug; 96(2):E110-E118. PubMed ID: 31625262 [TBL] [Abstract][Full Text] [Related]
2. "Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study. von Birgelen C; Kok MM; Sattar N; Zocca P; Doelman C; Kant GD; Löwik MM; van der Heijden LC; Sen H; van Houwelingen KG; Stoel MG; Louwerenburg JHW; Hartmann M; de Man FHAF; Linssen GCM; Doggen CJM; Tandjung K JACC Cardiovasc Interv; 2018 Mar; 11(5):448-459. PubMed ID: 29454724 [TBL] [Abstract][Full Text] [Related]
3. Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. Ploumen EH; Pinxterhuis TH; Zocca P; Roguin A; Anthonio RL; Schotborgh CE; Benit E; Aminian A; Danse PW; Doggen CJM; von Birgelen C; Kok MM Cardiovasc Diabetol; 2021 Oct; 20(1):217. PubMed ID: 34717627 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Yuan D; Jiang P; Zhu P; Jia S; Zhang C; Liu Y; Liu R; Xu J; Tang X; Zhao X; Gao R; Yang Y; Xu B; Gao Z; Yuan J Cardiovasc Diabetol; 2021 Jul; 20(1):143. PubMed ID: 34271936 [TBL] [Abstract][Full Text] [Related]
5. Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial. Bangalore S; Abhaichand R; Mullasari A; Jain R; Chand RKP; Arambam P; Kaul U Cardiovasc Revasc Med; 2019 Dec; 20(12):1075-1080. PubMed ID: 31036397 [TBL] [Abstract][Full Text] [Related]
6. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087 [TBL] [Abstract][Full Text] [Related]
7. Impact of unknown diabetes and prediabetes on clinical outcomes in "nondiabetic" Chinese patients after a primary coronary intervention. Wang H; Song Y; Tang X; Xu J; Jiang P; Jiang L; Gao Z; Chen J; Song L; Zhang Y; Zhao X; Qiao S; Yang Y; Gao R; Xu B; Yuan J; Gao L Nutr Metab Cardiovasc Dis; 2020 Apr; 30(4):644-651. PubMed ID: 32143897 [TBL] [Abstract][Full Text] [Related]
8. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial. van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries. Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ; Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593 [TBL] [Abstract][Full Text] [Related]
10. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial. Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378 [TBL] [Abstract][Full Text] [Related]
11. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies. Guedeney P; Claessen BE; Mehran R; Kandzari DE; Aquino M; Davis S; Tamis L; Wang JC; Othman I; Gigliotti OS; Haghighat A; Singh S; Lopez M; Giugliano G; Horwitz PA; Sorrentino S; Underwood P; Allocco D; Meredith IT; Batchelor W Catheter Cardiovasc Interv; 2019 Jul; 94(1):82-90. PubMed ID: 30666784 [TBL] [Abstract][Full Text] [Related]
12. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial. Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057 [TBL] [Abstract][Full Text] [Related]
13. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202 [TBL] [Abstract][Full Text] [Related]
14. Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c. Karayiannides S; Djupsjö C; Kuhl J; Hofman-Bang C; Norhammar A; Holzmann MJ; Lundman P Cardiovasc Diabetol; 2021 Jun; 20(1):122. PubMed ID: 34126971 [TBL] [Abstract][Full Text] [Related]
15. Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial. Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van Houwelingen KG; Danse PW; Schotborgh CE; Stoel MG; Scholte M; Linssen GCM; de Man FHAF; von Birgelen C Catheter Cardiovasc Interv; 2020 Nov; 96(5):E508-E515. PubMed ID: 32237060 [TBL] [Abstract][Full Text] [Related]
16. Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial. Tandjung K; Basalus MW; Sen H; Stoel MG; van Houwelingen KG; Louwerenburg JH; de Man FH; Linssen GC; Saïd SA; Kleijne MA; van der Palen J; von Birgelen C Catheter Cardiovasc Interv; 2013 Sep; 82(3):396-405. PubMed ID: 23359390 [TBL] [Abstract][Full Text] [Related]
17. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial. Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910 [TBL] [Abstract][Full Text] [Related]
18. Ten-year Outcomes After Drug-Eluting Stents or Bypass Surgery for Left Main Coronary Disease in Patients With and Without Diabetes Mellitus: The PRECOMBAT Extended Follow-Up Study. Jeong YJ; Ahn JM; Hyun J; Lee J; Kim JH; Yang Y; Choe K; Park H; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park SJ; Park DW J Am Heart Assoc; 2021 Jul; 10(14):e019834. PubMed ID: 34238026 [TBL] [Abstract][Full Text] [Related]
19. Final 5-year report of BIONYX comparing the thin-composite wire-strut zotarolimus-eluting stent versus ultrathin-strut sirolimus-eluting stent. van Vliet D; Ploumen EH; Pinxterhuis TH; Buiten RA; Aminian A; Schotborgh CE; Danse PW; Roguin A; Anthonio RL; Benit E; Zocca P; Doggen CJM; von Birgelen C Catheter Cardiovasc Interv; 2024 Jul; 104(1):1-9. PubMed ID: 38713843 [TBL] [Abstract][Full Text] [Related]
20. High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. Zocca P; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Hartmann M; Linssen GCM; Doggen CJM; von Birgelen C Cardiovasc Drugs Ther; 2018 Dec; 32(6):567-576. PubMed ID: 30143879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]